Offer Request Form

Order list is empty

Shikari® (Q-DAR) Daratumumab ELISA

Enzyme immunoassay for the quantitative determination of Daratumumab (Darzalex®) in serum and plasma.

This kit has been especially developed for the quantitative determination of Daratumumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

Daratumumab Drug Bank Accession Number is DB09331.

Daratumumab is a CD38-directed cytolytic monoclonal antibody that targets CD38+ multiple myeloma cells. Daratumumab is used alone or as an adjunct drug in the treatment of multiple myeloma and light chain amyloidosis. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary. 

All SHIKARI® ELISA kits are suitable for biosimilar work. 

All SHIKARI® ELISA kits are produced under ISO 13485 quality system and have CE IVD mark.

For technical inquiry, please contact

Required Volume (µl) 5
Total Time (min) 100
Sample Serum, plasma
Sample Number 96
Detection Limit (ng/mL) 10
Spike Recovery (%) Between 85-115
Shelf Life (year) 1
Assay type Qualitative
Species Reactivity Human
Storage conditions Store at +4°C. Please refer to protocols.
Shipping conditions At room temperature
# File Action
Instructions For Use Download
Safety Data Sheet (SDS) Download
Validation Report Download

Publications with this drug

# File Action